Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

GRACELL BIOTECHNOLOGIES INC.

(GRCL)
  Report
Delayed Nasdaq  -  04:00 2022-11-30 pm EST
3.250 USD   +2.20%
11/24Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences, November 23, 2022
AQ
11/23Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
PR
11/17Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Gracell Biotechnologies Stock Rises After Citigroup Reinstates Coverage

09/22/2022 | 01:10pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
CITIGROUP INC. 1.77% 48.41 Delayed Quote.-19.84%
GRACELL BIOTECHNOLOGIES INC. 2.20% 3.25 Delayed Quote.-46.19%
All news about GRACELL BIOTECHNOLOGIES INC.
11/24Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences, November 2..
AQ
11/23Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
PR
11/17Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award
AQ
11/16Gracell Biotechnologies : Wins 2022 Fierce Life Sciences Innovation Award - Form 6-K
PU
11/14Wall Street Set to Open Lower After Red Hot Week; Fed Gov Warns Inflation Fight Not Ove..
MT
11/14Transcript : Gracell Biotechnologies Inc., Q3 2022 Earnings Call, Nov 14, 202..
CI
11/14Top Premarket Decliners
MT
11/14Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Resultsáand Prov..
GL
11/14Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Resultsáand Prov..
GL
11/14Gracell Biotechnologies Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
More news
Analyst Recommendations on GRACELL BIOTECHNOLOGIES INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -101 M - -
Net Debt 2022 - - -
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 220 M 220 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 348
Free-Float 92,1%
Chart GRACELL BIOTECHNOLOGIES INC.
Duration : Period :
Gracell Biotechnologies Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GRACELL BIOTECHNOLOGIES INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 3,25 $
Average target price 14,67 $
Spread / Average Target 351%
EPS Revisions
Managers and Directors
Wei Cao Chairman & Chief Executive Officer
Kevin Yili Xie Chief Financial Officer
Jenny Ni Chief Technology Officer
Wendy Li Chief Medical Officer
Wendy Hayes Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GRACELL BIOTECHNOLOGIES INC.-46.19%220
MODERNA, INC.-30.74%67 581
IQVIA HOLDINGS INC.-22.73%40 495
LONZA GROUP AG-35.64%38 281
ALNYLAM PHARMACEUTICALS, INC.30.08%27 139
SEAGEN INC.-21.48%22 538